COO vs AVTR vs RGEN
161 measures in 16 categories, one definition each, computed from filings and market data.
COO69.2
The Cooper Companies, Inc.
Healthcare · Medical - Instruments & Supplies
$57.94 +0.94%$11.0B mkt cap
Score DNA
AVTR20.1
Avantor, Inc.
Healthcare · Medical - Instruments & Supplies
$16.42 +2.05%$11.1B mkt cap
Score DNA
RGEN64.3
Repligen Corporation
Healthcare · Medical - Instruments & Supplies
$175.42 −4.75%$11.1B mkt cap
Score DNA
Price, rebased to 100 three years ago
COO AVTR RGEN · weekly adjusted closesSmart money 8Valuation 16Profitability (TTM) 12Returns on capital 11Growth 17Margin history & stability 7Liquidity (latest quarter) 7Leverage & solvency (latest quarter) 13Efficiency 11Cash flow & earnings quality 7Dividends & buybacks 9Scores & forensic checks 15Per share 7Size (TTM) 8Price performance 9Technicals 4
● marks the highest or lowest value where that direction is plainly stronger (margins, returns, coverage, leverage); multiples and yields are left unmarked. Bars show each stock's percentile within its own industry. n/a: the measure does not apply to lenders and insurers.
Smart money
8 measures| Measure | COO | AVTR | RGEN |
|---|---|---|---|
| Insider open-market buys, 180d | 5 | 2 | 0 |
| Insider $ bought, 180d | $1.88M | $0.29M | — |
| Congress purchases, 180d | 15 | 0 | 0 |
| Last Congress purchase | 2026-09-17 | — | — |
| 13F net change in holders | +2 | +26 | +38 |
| ETFs adding shares, 30d | 806 | 252 | 378 |
| ETFs trimming, 30d | 628 | 182 | 257 |
| Net ETF funds, 30d | +178 | +70 | +121 |
Valuation
16 measures| Measure | COO | AVTR | RGEN |
|---|---|---|---|
| P/E (TTM) | 19.3x
13th
|
— | 268.1x
87th
|
| PEG (P/E ÷ 3-yr EPS CAGR) | 0.67
29th
|
— | — |
| Price / sales | 2.6x
58th
|
1.7x
29th
|
14.2x
96th
|
| Price / book | 1.3x
17th
|
2.0x
29th
|
5.3x
75th
|
| Price / tangible book | 4.7x
13th
|
— | 11.9x
80th
|
| Price / free cash flow | 16.3x
24th
|
24.4x
43rd
|
100.5x
90th
|
| Price / operating cash flow | 10.7x
18th
|
18.6x
50th
|
82.6x
95th
|
| Enterprise value | $13.4B
68th
|
$14.5B
72nd
|
$11.0B
64th
|
| EV / sales | 3.2x
62nd
|
2.2x
33rd
|
14.0x
96th
|
| EV / EBITDA | 14.7x
25th
|
115.7x
100th
|
64.8x
90th
|
| EV / EBIT | 25.5x
41st
|
— | 142.2x
94th
|
| EV / free cash flow | 19.8x
14th
|
31.9x
57th
|
99.5x
90th
|
| Earnings yield | 5.2%
92nd
|
-5.2%
28th
|
0.4%
48th
|
| FCF yield | 6.2%
80th
|
4.1%
64th
|
1.0%
24th
|
| Operating cash flow yield | 9.4%
84th
|
5.4%
56th
|
1.2%
16th
|
| Graham number (per share) | $53.45
57th
|
— | $24.80
29th
|
Profitability (TTM)
12 measures| Measure | COO | AVTR | RGEN |
|---|---|---|---|
| Gross margin | 63.6%
80th
|
31.8%
16th
|
51.1%
44th
|
| EBITDA margin | 21.5%
67th
|
1.9%
17th
|
21.7%
71st
|
| Operating margin | 12.9%
75th
|
-4.4%
8th
|
8.3%
42nd
|
| EBIT margin | 12.4%
67th
|
-4.5%
21st
|
9.9%
58th
|
| Net margin | 13.5%
79th
|
-8.8%
29th
|
5.3%
62nd
|
| NOPAT margin | 15.9%
75th
|
-3.4%
8th
|
6.6%
50th
|
| FCF margin | 16.0%
83rd
|
6.9%
42nd
|
14.1%
75th
|
| Operating cash flow margin | 24.4%
88th
|
9.1%
38th
|
17.2%
75th
|
| R&D / revenue | 4.0%
21st
|
0.0%
0th
|
7.0%
62nd
|
| SG&A / revenue | 44.5%
79th
|
18.3%
8th
|
36.9%
50th
|
| Stock comp / revenue | 0.0%
0th
|
0.6%
16th
|
3.1%
68th
|
| Effective tax rate | -23.3%
0th
|
21.0%
36th
|
20.3%
24th
|
Returns on capital
11 measures| Measure | COO | AVTR | RGEN |
|---|---|---|---|
| ROE (on average equity) | 6.8%
71st
|
-9.7%
29th
|
2.0%
50th
|
| ROA | 4.6%
68th
|
-4.7%
32nd
|
1.4%
52nd
|
| ROIC | 6.3%
60th
|
-2.5%
12th
|
2.6%
28th
|
| ROCE | 4.9%
52nd
|
-2.9%
24th
|
2.7%
40th
|
| Return on tangible assets | 4.2%
56th
|
-2.4%
24th
|
2.6%
48th
|
| Cash ROIC (OCF / invested capital) | 9.6%
64th
|
6.6%
32nd
|
6.8%
36th
|
| Gross profitability (GP / assets) | 21.3%
40th
|
18.0%
24th
|
13.6%
4th
|
| ROIC, 3-yr average | 5.2%
67th
|
1.8%
48th
|
0.7%
43rd
|
| ROIC, 5-yr average | 4.3%
67th
|
3.6%
57th
|
4.5%
71st
|
| ROE, 5-yr average | 5.2%
62nd
|
6.0%
71st
|
3.3%
57th
|
| Incremental ROIC | 408.5%
96th
|
64.0%
58th
|
114.2%
71st
|
Growth
17 measures| Measure | COO | AVTR | RGEN |
|---|---|---|---|
| Revenue growth (TTM YoY) | 4.7%
35th
|
-1.6%
17th
|
16.5%
87th
|
| Revenue growth (QoQ) | -1.4%
4th
|
7.0%
64th
|
5.1%
52nd
|
| Revenue CAGR, 3 yr | 6.4%
67th
|
-2.9%
10th
|
3.3%
43rd
|
| Revenue CAGR, 5 yr | 8.3%
53rd
|
-1.4%
11th
|
9.1%
63rd
|
| Gross profit CAGR, 3 yr | 5.6%
67th
|
-5.6%
10th
|
2.4%
43rd
|
| Operating income CAGR, 3 yr | 2.8%
36th
|
— | -21.4%
7th
|
| Net income growth (TTM YoY) | 39.8%
80th
|
— | — |
| Net income CAGR, 3 yr | 27.5%
82nd
|
— | -30.6%
9th
|
| EPS growth (TTM YoY) | 45.1%
80th
|
— | — |
| EPS CAGR, 3 yr | 28.8%
82nd
|
— | -30.5%
9th
|
| EPS CAGR, 5 yr | -45.0%
0th
|
— | -16.1%
36th
|
| FCF growth (TTM YoY) | 64.6%
76th
|
-18.2%
6th
|
4.6%
47th
|
| FCF CAGR, 3 yr | 45.2%
79th
|
-14.2%
0th
|
29.4%
57th
|
| Operating cash flow CAGR, 3 yr | 22.4%
62nd
|
-11.2%
0th
|
-3.2%
12th
|
| Book value CAGR, 3 yr | 4.5%
71st
|
3.9%
67th
|
2.5%
57th
|
| Dividend CAGR, 3 yr | — | — | — |
| Sustainable growth rate | 6.8%
50th
|
— | 2.0%
21st
|
Margin history & stability
7 measures| Measure | COO | AVTR | RGEN |
|---|---|---|---|
| Gross margin, 3-yr average | 65.7%
77th
|
32.9%
0th
|
45.7%
32nd
|
| Operating margin, 3-yr average | 16.0%
77th
|
7.2%
50th
|
2.4%
36th
|
| Net margin, 3-yr average | 11.0%
82nd
|
2.3%
50th
|
1.1%
45th
|
| FCF margin, 3-yr average | 10.4%
64th
|
8.7%
45th
|
16.5%
86th
|
| Revenue stability (0-1) | 0.99
83rd
|
0.71
48th
|
0.68
35th
|
| Earnings stability (0-1) | 0.37
48th
|
0.27
39th
|
0.51
57th
|
| Margin stability (0-1) | 0.98
77th
|
0.97
68th
|
0.87
0th
|
Liquidity (latest quarter)
7 measures| Measure | COO | AVTR | RGEN |
|---|---|---|---|
| Cash & short-term investments | $154.7M
12th
|
$306.8M
48th
|
$810.4M
80th
|
| Net cash (− = net debt) | −$2.4B
28th
|
−$3.4B
20th
|
$119.5M
72nd
|
| Working capital | $414.9M
40th
|
$1.1B
72nd
|
$1.1B
68th
|
| Current ratio | 1.22
8th
|
1.78
28th
|
9.05
92nd
|
| Quick ratio | 0.73
4th
|
1.18
24th
|
7.64
92nd
|
| Cash ratio (cash + ST investments / current liabilities) | 0.08
4th
|
0.22
24th
|
6.11
92nd
|
| Defensive interval (days) | 160 days
12th
|
222 days
28th
|
1,053 days
96th
|
Leverage & solvency (latest quarter)
13 measures| Measure | COO | AVTR | RGEN |
|---|---|---|---|
| Total debt | $2.5B
72nd
|
$3.7B
80th
|
$690.9M
40th
|
| Debt / equity | 0.31
33rd
|
0.66
67th
|
0.33
38th
|
| Net debt / equity | 0.29
54th
|
0.60
67th
|
−0.06
38th
|
| Debt / assets | 20.1%
32nd
|
31.9%
60th
|
23.4%
40th
|
| Debt / capital | 23.4%
33rd
|
39.6%
67th
|
24.7%
38th
|
| Debt / EBITDA | 2.79
45th
|
29.51
100th
|
4.06
60th
|
| Net debt / EBITDA | 2.62
55th
|
27.06
100th
|
−0.70
20th
|
| Interest coverage (EBIT / interest) | 5.6x
67th
|
−1.6x
19th
|
3.5x
57th
|
| Cash interest coverage | 10.9x
81st
|
3.3x
33rd
|
6.1x
52nd
|
| Debt payback (years of OCF) | 2.5 yrs
32nd
|
6.2 yrs
64th
|
5.1 yrs
50th
|
| Liabilities / assets | 34.3%
36th
|
51.4%
64th
|
28.4%
28th
|
| IS credit model rating | A- | B | A |
| Implied credit spread (bps) | 175
40th
|
750
88th
|
150
32nd
|
Efficiency
11 measures| Measure | COO | AVTR | RGEN |
|---|---|---|---|
| Asset turnover | 0.34
12th
|
0.54
48th
|
0.27
4th
|
| Fixed asset turnover | 1.98
12th
|
8.50
88th
|
2.77
28th
|
| Inventory turnover | 1.7
12th
|
5.6
92nd
|
2.2
28th
|
| Receivables turnover | 5.4
24th
|
5.7
36th
|
5.0
12th
|
| Days sales outstanding | 68 days
76th
|
64 days
64th
|
73 days
88th
|
| Days inventory outstanding | 212 days
88th
|
66 days
8th
|
163 days
72nd
|
| Days payables outstanding | 60 days
64th
|
59 days
60th
|
28 days
12th
|
| Cash conversion cycle (days) | 220 days
92nd
|
70 days
16th
|
208 days
88th
|
| Capex / revenue | 8.4%
92nd
|
2.2%
25th
|
3.1%
33rd
|
| Capex / depreciation | 0.93
88th
|
0.34
29th
|
0.26
12th
|
| Operating expense ratio | 41.5%
46th
|
24.5%
12th
|
47.2%
62nd
|
Cash flow & earnings quality
7 measures| Measure | COO | AVTR | RGEN |
|---|---|---|---|
| Operating cash flow / net income | 1.81
40th
|
— | 3.25
73rd
|
| FCF / net income | 1.19
40th
|
— | 2.67
73rd
|
| FCF / operating cash flow | 65.6%
38th
|
76.2%
52nd
|
82.1%
71st
|
| Capex / operating cash flow | 34.4%
62nd
|
23.8%
48th
|
17.9%
29th
|
| Accruals ratio | -3.7%
68th
|
-9.6%
32nd
|
-3.2%
76th
|
| Sloan accruals ratio | -8.8%
8th
|
5.9%
88th
|
1.4%
72nd
|
| Earnings quality score (0-1) | 1.00
47th
|
— | 1.00
47th
|
Scores & forensic checks
15 measures| Measure | COO | AVTR | RGEN |
|---|---|---|---|
| IS score | 69
84th
|
20
0th
|
64
72nd
|
| IS profitability | 61
84th
|
16
8th
|
24
40th
|
| IS growth | 60
57th
|
31
9th
|
68
87th
|
| IS value | 45
64th
|
40
28th
|
41
44th
|
| IS momentum | 88
74th
|
34
9th
|
95
100th
|
| IS risk (safety) | 80
48th
|
30
8th
|
100
72nd
|
| IS quality | 79
80th
|
47
32nd
|
73
72nd
|
| IS balance sheet | 56
52nd
|
34
12th
|
74
60th
|
| IS earnings quality | 74
72nd
|
46
44th
|
74
68th
|
| IS cash flow | 70
80th
|
35
32nd
|
61
68th
|
| Piotroski F-score (0-9) | 6
48th
|
6
48th
|
8
84th
|
| Altman Z-score | 3.3
56th
|
1.5
12th
|
6.5
76th
|
| Beneish M-score | −2.62
74th
|
−2.98
26th
|
−2.66
52nd
|
| Ohlson O-score | −9.33
28th
|
−7.28
68th
|
−9.84
16th
|
| IS credit score | 66
56th
|
29
12th
|
72
68th
|
Size (TTM)
8 measures| Measure | COO | AVTR | RGEN |
|---|---|---|---|
| Market cap | $11.0B
64th
|
$11.1B
68th
|
$11.1B
72nd
|
| Revenue | $4.2B
68th
|
$6.6B
80th
|
$785.1M
32nd
|
| EBITDA | $910.3M
80th
|
$125.3M
40th
|
$170.1M
44th
|
| Net income | $570.3M
84th
|
−$578.0M
8th
|
$41.5M
52nd
|
| Free cash flow | $678.0M
80th
|
$454.7M
76th
|
$110.8M
36th
|
| Total assets | $12.7B
76th
|
$11.6B
72nd
|
$3.0B
40th
|
| Shareholders' equity | $8.3B
88th
|
$5.6B
72nd
|
$2.1B
44th
|
| Employees | 15,000
76th
|
13,500
64th
|
2,000
32nd
|
Price performance
9 measures| Measure | COO | AVTR | RGEN |
|---|---|---|---|
| 1 day | +0.9% | +2.0% | −4.8% |
| 1 week | +6.6% | +4.8% | +0.9% |
| 1 month | +7.7% | +3.5% | −1.6% |
| 3 months | −19.1% | +54.0% | +20.6% |
| 6 months | −17.3% | +92.7% | +33.7% |
| Year to date | −28.6% | +43.3% | +6.7% |
| 1 year | −15.7% | +18.4% | +17.3% |
| 3 years, cumulative | −25.4% | −21.6% | +12.2% |
| 5 years, cumulative | −43.5% | −59.5% | −32.2% |
Technicals
4 measures| Measure | COO | AVTR | RGEN |
|---|---|---|---|
| RSI 14 | 50.3 | 68.4 | 48.8 |
| From 52-week high | −35.5% | −0.1% | −11.8% |
| From 52-week low | +13.6% | +125.9% | +73.7% |
| Beta | 0.82 | 0.94 | 1.08 |
InsiderStreet reports findings from filings and market data. A comparison is not a recommendation to buy or sell either stock.Every figure is computed in code · data as of 2026-10-17